Type 1, Type 2 Myocardial Infarction and Non-Ischemic Myocardial Injury-Opinion from the Front Lines.


Journal

The American journal of medicine
ISSN: 1555-7162
Titre abrégé: Am J Med
Pays: United States
ID NLM: 0267200

Informations de publication

Date de publication:
08 2022
Historique:
received: 22 03 2022
accepted: 22 03 2022
pubmed: 29 3 2022
medline: 4 8 2022
entrez: 28 3 2022
Statut: ppublish

Résumé

Differentiating patients with type 1 and type 2 myocardial infarction (MI) and acute non-ischemic myocardial injury continues to be a problem for many clinicians. Type 1 MI is the most easily defined. It involves the rise and fall of blood troponin measurements (only falling values if the patient arrives late) with an appropriate clinical observation consistent with myocardial ischemia. Diagnosis and therapy of type 1 MI are well understood and usually present no problem to the physician. The clinical scenarios leading to type 2 MI and non-ischemic myocardial injury are, however, often fraught with greater degrees of uncertainty. In addition, therapy for these latter 2 entities is poorly defined. This review will present 3 patient scenarios that should help clinicians understand the difference between these 3 entities as well as possible therapeutic interventions.

Identifiants

pubmed: 35341772
pii: S0002-9343(22)00203-0
doi: 10.1016/j.amjmed.2022.03.004
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

935-938

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Auteurs

Joseph S Alpert (JS)

University of Arizona College of Medicine, Tucson; Editor in Chief, The American Journal of Medicine. Electronic address: jalpert@shc.arizona.edu.

Allan S Jaffe (AS)

Mayo Clinic, Rochester, Minn.

Harvey D White (HD)

Green Lane Cardiovascular Service, Auckland City Hospital, New Zealand.

Kristian A Thygesen (KA)

Aarhus University Hospital, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH